Vinai Gondi, MD, on Treating Brain Metastases, Preserving Cognitive Function
2018 ASTRO Annual Meeting
Vinai Gondi, MD, of Northwestern Medicine, discusses the early results of a phase III NRG Oncology trial that suggests a practice change in treating brain metastases: avoiding the hippocampus when delivering whole-brain radiotherapy (Abstract LBA9).
Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).
Daniel E. Spratt, MD, of the University of Michigan, discusses a large-scale gene-expression analysis and meta-analysis of RTOG trials on androgen receptor activity and radiotherapeutic sensitivity in African American men with prostate cancer (Abstract 4).
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation and androgen-deprivation therapy; the efficacy and toxicity of SBRT; conventional vs hypofractionated radiation therapy; and dose escalation (Scientific Symposium 08).
David Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA10).
Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with deintensified chemoradiotherapy, and the costs of dose de-escalation (Scientific Session 31).